We are live on ! Find out more
WP

Woodline Partners Portfolio holdings

AUM $26.4B
1-Year Est. Return 44.85%
This Fund
S&P 500
This Quarter Est. Return
+2.52%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
AUM
$7.16B
AUM Growth
+$666M
Cap. Flow
+$831M
Cap. Flow %
11.61%
Top 10 Hldgs %
17.05%
Holding
983
New
189
Increased
207
Reduced
145
Closed
240

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$73.2M
2
PANW icon
Palo Alto Networks
PANW
+$59.8M
3
ALKS icon
Alkermes
ALKS
+$55.3M
4
ACN icon
Accenture
ACN
+$53.8M
5
JNJ icon
Johnson & Johnson
JNJ
+$53M

Sector Composition

Rank Sector Weight
1 Healthcare 36.05%
2 Technology 29.2%
3 Financials 8.76%
4 Industrials 7.7%
5 Communication Services 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BIDU icon
301
Baidu
BIDU
$37B
$4.77M 0.07%
+40,600
New +$5.54M
DOCN icon
302
DigitalOcean
DOCN
$14.4B
$4.74M 0.07%
+130,996
New +$5.51M
RDNT icon
303
RadNet
RDNT
$5.29B
$4.72M 0.07%
232,161
+15,103
+7% +$304K
PCVX icon
304
Vaxcyte
PCVX
$8.4B
$4.71M 0.07%
196,429
-269,895
-58% -$6.84M
THAC
305
DELISTED
Thrive Acquisition Corporation Class A ordinary shares
THAC
$4.7M 0.07%
+463,701
New +$4.69M
AZPN
306
DELISTED
Aspen Technology Inc
AZPN
$4.69M 0.07%
+19,687
New +$4.09M
DHBC
307
DELISTED
DHB Capital Corp. Class A common stock
DHBC
$4.67M 0.07%
475,034
+165,095
+53% +$1.62M
COCH icon
308
Envoy Medical
COCH
$52M
$4.67M 0.07%
475,000
HUM icon
309
Humana
HUM
$43.6B
$4.66M 0.07%
9,611
-64,640
-87% -$31.4M
IGMS
310
DELISTED
IGM Biosciences
IGMS
$4.55M 0.06%
200,047
GOSS icon
311
Gossamer Bio
GOSS
$87.3M
$4.54M 0.06%
378,623
-748,186
-66% -$9.29M
ISEE
312
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.54M 0.06%
+252,815
New +$3.32M
VTYX
313
DELISTED
Ventyx Biosciences
VTYX
$4.49M 0.06%
128,663
+8,663
+7% +$192K
AEAE
314
DELISTED
AltEnergy Acquisition Corp
AEAE
$4.49M 0.06%
450,000
BRSL
315
Brightstar Lottery PLC
BRSL
$2.01B
$4.47M 0.06%
283,088
+72,305
+34% +$1.35M
ACII
316
DELISTED
Atlas Crest Investment Corp. II
ACII
$4.47M 0.06%
455,000
BOAS
317
DELISTED
BOA Acquisition Corp.
BOAS
$4.47M 0.06%
450,000
FTAA
318
DELISTED
FTAC Athena Acquisition Corp. Class A Ordinary Share
FTAA
$4.47M 0.06%
449,975
+50,000
+13% +$494K
AGAC
319
DELISTED
African Gold Acquisition Corp
AGAC
$4.46M 0.06%
450,000
+300,000
+200% +$2.96M
VOR icon
320
Vor Biopharma
VOR
$1.27B
$4.42M 0.06%
55,556
TSPQ
321
DELISTED
TCW Special Purpose Acquisition Corp.
TSPQ
$4.41M 0.06%
449,999
OSI
322
DELISTED
Osiris Acquisition Corp.
OSI
$4.39M 0.06%
450,000
CPUH
323
DELISTED
Compute Health Acquisition Corp.
CPUH
$4.38M 0.06%
443,553
MIT
324
DELISTED
Mason Industrial Technology, Inc.
MIT
$4.36M 0.06%
445,000
PYCR
325
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
$4.36M 0.06%
+147,341
New +$4.26M

Similar funds

Woodline Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Woodline Partners held 983 positions worth $7.16B, up 10% from $6.49B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Woodline Partners deployed $831M of net new capital in Q3 2022, opening 189 new positions and adding to 207 existing holdings. Its largest new stake was Amazon: 683,398 shares worth $77.2M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Eli Lilly, an estimated $73.2M trimmed.

  • Woodline Partners's largest Q3 2022 buy was Amazon: 683,398 shares worth $77.2M.
  • Woodline Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $146M increase.
  • Woodline Partners's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $73.2M.
  • Woodline Partners fully exited Palo Alto Networks in Q3 2022, selling an estimated $59.8M.
  • Woodline Partners's ten largest holdings make up 17% of its $7.16B portfolio in Q3 2022.
  • Woodline Partners opened 189 new positions and closed 240 in Q3 2022.
  • Woodline Partners's portfolio value rose 10% quarter-over-quarter to $7.16B.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.